



ASSIGNMENT

We,

Stephen A. Goff	residing at	227 Dunhill Drive Durham, NC 27713
Lyle D. Crossland	residing at	108 Pinchot Lane Chapel Hill, NC 27514
Laura S. Privalle	residing at	3101 Wild Meadow Drive Durham, NC 27705

for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, do hereby sell and assign to CIBA-GEIGY Corporation, a New York corporation, of 444 Saw Mill River Road, Ardsley, New York, its successors, assigns and legal representatives all my right, title and interest, in the United States, its territories and possessions, and in any and all countries foreign to the United States, in and to the invention entitled:

**CONTROL OF GENE EXPRESSION IN PLANTS BY RECEPTOR MEDIATED
TRANSACTIVATION IN THE PRESENCE OF A CHEMICAL LIGAND**

invented by us and described in the application for United States Letters Patent

☐ executed on even date herewith


☒ Serial No. 08/398,037, filed March 3, 1995


including (i) authorization to file corresponding applications for patents or other similar legal protection and continuations, continuations-in-part, supplementary disclosures, divisions or extensions thereof in any country foreign to the United States in which an assignee can apply for a patent or similar legal protection, (ii) any and all rights under international treaties, conventions, agreements, charters and laws in respect of the said invention, especially the right to claim priority based on the said application for United States Letters Patent, (iii) any and all Letters Patent or similar legal protection, which may be granted therefore, and all divisions, reissues, continuations and extensions thereof, said interest being the entire ownership of the said Letters Patent or similar legal protection when granted, to be held and enjoyed by CIBA-GEIGY Corporation, its successors, assigns or other legal representatives, to the full end of the term for which said Letter

Patent or similar legal protection may be granted, and hereby further covenant and agree that we will at any time upon request, without charge to, but at the expense of CIBA-GEIGY Corporation, execute such additional assignments and other lawful papers as CIBA-GEIGY Corporation, may deem necessary or desirable, testify in any legal proceeding, execute all divisional, continuing, reissue and extension applications, make all rightful oaths, and generally do everything possible to aid CIBA-GEIGY Corporation, its successors, assigns, and legal representatives, to obtain and enforce proper patent protection for said invention.

Signed at Research Triangle Park, NC, this 20th day of April, 1995.


Stephen A. Goff


Lyle D. Crossland


Laura S. Privalle

ASSIGNMENT

Whereas, Novartis Corporation, 608 Fifth Avenue, New York, NY 10020, a corporation of New York, is the assignee and legal owner of the entire right, title and interest in each of United States Patents 5,880,333 and 6,147,282;

Whereas, Novartis Corporation was formerly known as Ciba-Geigy Corporation, the change of name having been recorded in the Patent and Trademark Office on October 13, 1998 (Reel 9507, Frames 0112-0114); and


Whereas, in accordance with a resolution of the Board of Directors of Ciba-Geigy Corporation (now Novartis Corporation) made on December 20, 1996, Novartis Corporation wishes to assign its entire interest in each of United States Patents 5,880,333 and 6,147,282 and certain related patent applications to Novartis Finance Corporation, 608 Fifth Avenue, New York, NY 10020, a corporation of New York, and said Novartis Finance Corporation wishes to acquire Novartis Corporation's interest in said patents and patent applications.

Now, therefore, Novartis Corporation hereby assigns to Novartis Finance Corporation and its successors and assigns its entire right, title and interest in (1) (a) each of United States Patents 5,880,333 and 6,147,282, (b) any and all applications for reissues of said patents, (c) any and all reissues of said patents that may be issued and/or granted, (d) any and all applications for extensions of said patents (including reissue patents) and for reexamination certificates for said patents (including reissue patents) and (e) any and all extensions of said patents (including reissue patents) that may be issued and/or granted and reexamination certificates that may be issued for said patents (including reissue patents), and (2) (a) any and all United States patent applications, whether pending or abandoned, that are continuations and divisions (including further continuations and divisions such as, but not limited to, continuations and divisions of continuations) of the applications which issued as United States Patents 5,880,333 and 6,147,282, (b) any and all United States patents that may have been or, in the future, that may be issued and/or granted on all of said applications, (c) any and all applications for reissues of said patents, (d) any and all reissues of said patents that may be issued and/or granted, (e) any and all applications for extensions of said patents (including reissue patents) and for reexamination certificates for said patents (including reissue patents) and (f) any and all extensions of said patents (including reissue patents) that may be issued and/or granted and reexamination certificates that may be issued for said patents (including reissue patents), including, in the case of all patents (including reissue patents) within the scopes of (1) and (2), the right to sue, and to obtain damages, for past infringement, said right, title and interest conveyed herein by Novartis Corporation to Novartis Finance Corporation constituting the entire right, title and interest in said patents (including reissue patents), applications, extensions and reexamination certificates.

In witness whereof, Novartis Corporation has caused this Assignment to be signed by its duly authorized corporate officer.

Signed this 24th day of August 2004.

Novartis Corporation

A handwritten signature in black ink, appearing to read 'SH Hartman', written over a horizontal line.

Steven H. Hartman
Vice-President

ASSIGNMENT

Whereas, Novartis Finance Corporation, 608 Fifth Avenue, New York, NY 10020, a corporation of New York, is the assignee and legal owner of the entire right, title and interest in each of United States Patents 5,880,333 and 6,147,282 by virtue of an Assignment from Novartis Corporation dated August 24, 2004; and


Whereas, in accordance with a resolution of its Board of Directors made on October 31, 2000, Novartis Finance Corporation wishes to assign its entire interest in each of United States Patents 5,880,333 and 6,147,282 and certain related patent applications to Syngenta Investment Corporation, 2200 Concord Pike, Wilmington, DE 19803, a corporation of Delaware, and said Syngenta Investment Corporation wishes to acquire Novartis Finance Corporation's interest in said patents and patent applications.

Now, therefore, Novartis Finance Corporation hereby assigns to Syngenta Investment Corporation and its successors and assigns its entire right, title and interest in (1) (a) each of United States Patents 5,880,333 and 6,147,282, (b) any and all applications for reissues of said patents, (c) any and all reissues of said patents that may be issued and/or granted, (d) any and all applications for extensions of said patents (including reissue patents) and for reexamination certificates for said patents (including reissue patents) and (e) any and all extensions of said patents (including reissue patents) that may be issued and/or granted and reexamination certificates that may be issued for said patents (including reissue patents), and (2) (a) any and all United States patent applications, whether pending or abandoned, that are continuations and divisions (including further continuations and divisions such as, but not limited to, continuations and divisions of continuations) of the applications which issued as United States Patents 5,880,333 and 6,147,282, (b) any and all United States patents that may have been or, in the future, that may be issued and/or granted on all of said applications, (c) any and all applications for reissues of said patents, (d) any and all reissues of said patents that may be issued and/or granted, (e) any and all applications for extensions of said patents (including reissue patents) and for reexamination certificates for said patents (including reissue patents) and (f) any and all extensions of said patents (including reissue patents) that may be issued and/or granted and reexamination certificates that may be issued for said patents (including reissue patents), including, in the case of all patents (including reissue patents) within the scopes of (1) and (2), the right to sue, and to obtain damages, for past infringement, said right, title and interest conveyed herein by Novartis Finance Corporation to Syngenta Investment Corporation constituting the entire right, title and interest in said patents (including reissue patents), applications, extensions and reexamination certificates.

In witness whereof, Novartis Finance Corporation has caused this Assignment to be signed by its duly authorized corporate officer.

Signed this 24th day of August 2004.

Novartis Finance Corporation


Wayne P. Merkelson
Vice-President